Novo Nordisk's adjusted Wegovy oral drug sales for the third quarter were DKK 5.39 billion, and the market expected DKK 4.64 billion.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.